
Novo Nordisk's Board Reshuffle Amid Leadership Turmoil
Novo Nordisk is undergoing a significant boardroom shake-up with seven directors, including the chairman, not seeking re-election due to disagreements with its major shareholder, the Novo Nordisk Foundation, over governance and strategic direction. This follows recent leadership changes, profit warnings, and increased competition affecting its market valuation, especially from rivals like Eli Lilly.


